Statins in coronary bypass surgery: rationale and clinical use. (Q35604889)

9 August 2017

1 reference

title

Statins in coronary bypass surgery: rationale and clinical use. (English)

1 reference

9 August 2017

0 references

Francesco Alamanni

6

0 references

Elena Tremoli

object named as

Elena Tremoli

series ordinal

2

0 references

Aldo Cannata

series ordinal

5

object named as

Aldo Cannata

1 reference

9 August 2017

8

Alessandro Parolari

1 reference

9 August 2017

7

Paolo Biglioli

1 reference

9 August 2017

4

Marina Camera

1 reference

9 August 2017

José Pablo Werba

1

1 reference

9 August 2017

Paola Massironi

series ordinal

3

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 December 2003

1 reference

The Annals of Thoracic Surgery

9 August 2017

published in

1 reference

9 August 2017

volume

76

1 reference

9 August 2017

issue

6

1 reference

9 August 2017

page(s)

2132-2140

1 reference

ACC/AHA Guidelines for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1991 Guidelines for Coronary Artery Bypass Graft [...]

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

Regulation of the mevalonate pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

Pathogenesis of atherosclerosisand the role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

The influence of the combined presence of diabetes mellitus and hypercholesterolaemia on the function and morphology of experimental vein grafts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

Comparison of response to injury in organ culture of human saphenous vein and internal mammary artery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

Enhancement of tissue factor expression by vein segments exposed to coronary arterial hemodynamics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

Endothelial cell injury in cardiovascular surgery: the intimal hyperplastic response.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

HMG-CoA reductase inhibitor mobilizes bone marrow--derived endothelial progenitor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

Preoperative lipid-control with simvastatin reduces the risk of postoperative thrombocytosis and thrombotic complications following CABG

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

Effects of selective LDL-apheresis and pravastatin therapy on platelet function in familial hypercholesterolaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

Effects of synvinolin on platelet aggregation and thromboxane B2 synthesis in type IIa hypercholesterolemic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

No influence of simvastatin treatment on platelet function in vivo in patients with hypercholesterolemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

Platelet Deposition on Eroded Vessel Walls at a Stenotic Shear Rate Is Inhibited by Lipid-Lowering Treatment With Atorvastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different statins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

Transferable lipids in oxidized low-density lipoprotein stimulate plasminogen activator inhibitor-1 and inhibit tissue-type plasminogen activator release from endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

Cellular antioxidant effects of atorvastatin in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

Simvastatin decreases aldehyde production derived from lipoprotein oxidation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

HMG-CoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

Pleiotropic effects of statins and their clinical significance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

Vastatins Inhibit Tissue Factor in Cultured Human Macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

Fluvastatin reduces tissue factor expression and macrophage accumulation in carotid lesions of cholesterol-fed rabbits in the absence of lipid lowering

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

A pharmacoepidemiological assessment of the effect of statins and fibrates on fibrinogen concentration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

Atherosclerosis — An Inflammatory Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

Inflammation and atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

Antiinflammatory and immunomodulatory properties of statins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

Statin therapy and the acute inflammatory response after coronary artery bypass grafting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

Can statins reduce the inflammatory response to cardiopulmonary bypass? A clinical study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

Increased secretion of basement membrane-degrading metalloproteinases in pig saphenous vein into carotid artery interposition grafts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

Simvastatin inhibits human saphenous vein neointima formation via inhibition of smooth muscle cell proliferation and migration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

HMG CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

The relation of risk factors to the development of atherosclerosis in saphenous-vein bypass grafts and the progression of disease in the native circulation. A study 10 years after aortocoronary bypass surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

Hypercholesterolemia and experimental vein grafts: accelerated development of intimal hyperplasia and an increase in abnormal vasomotor function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

Effect of an aggressive lipid-lowering strategy on progression of atherosclerosis in the left main coronary artery from patients in the post coronary artery bypass graft trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

Preoperative lipid control with simvastatin reduces the risk for graft failure already 1 year after myocardial revascularization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. Cholesterol and Recurrent Events CARE Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2803%2900820-8

10.1016/S0003-4975(03)00820-8

7 January 2021

Identifiers

DOI

1 reference

9 August 2017

1 reference